Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

被引:0
作者
Svenja Wagener-Ryczek
Carina Heydt
Juliane Süptitz
Sebastian Michels
Markus Falk
Christina Alidousty
Jana Fassunke
Michaela Angelika Ihle
Markus Tiemann
Lukas Heukamp
Jürgen Wolf
Reinhard Büttner
Sabine Merkelbach-Bruse
机构
[1] University Hospital of Cologne,Institute of Pathology
[2] University Hospital of Cologne,Department I of Internal Medicine
[3] Insitute for Haematopathology,undefined
[4] NEO New Oncology GmbH,undefined
来源
BMC Cancer | / 20卷
关键词
NSCLC; EGFR; TKI; Acquired resistance; Afatinib; Erlotinib; Gefitinib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 214 条
[1]  
Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
[2]  
Ma J(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[3]  
Zou Z(2009)Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene. 28 S24-S31
[4]  
Jemal A(2013)Afatinib, Erlotinib and Gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review Oncol Research and Treatment 36 510-518
[5]  
Maemondo M(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[6]  
Inoue A(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[7]  
Kobayashi K(2015)AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 1689-1699
[8]  
Sugawara S(2005)Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 22-933
[9]  
Oizumi S(2012)HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Cancer Discov 2 922-928
[10]  
Isobe H(2017)Distinct Afatinib resistance mechanisms identified in lung adenocarcinoma harboring an EGFR mutation Mol Cancer Res 15 915-EE31